INTRODUCTION

An overview is provided regarding some of the most commonly used measures to assess pain in adults. These measures are appropriate for both general and rheumatologic pain populations. Most measures are easy to use in clinical settings and all are validated for use in research. A number of well-known measures such as the Visual Analog Scale, Numeric Rating Scale, McGill Pain Questionnaire, and the Short Form 36 bodily pain subscale were described in a previous issue (1). Pain is complex, and thus it is important to conduct a comprehensive assessment. Here, we discuss several other measures that are helpful for assessing the severity, location, and quality of pain as well as pain-related interference in functioning. Further, knowing whether the pain is focal (ie, isolated to one area of the body) or more widespread can indicate the degree to which the pain is centralized in nature (2–5) and thus inform the treatment approach to the care of rheumatology patients.

However, the assessment of pain (location, severity, and quality) and its impact on functioning cannot possibly tell the full story. Pain is a biopsychosocial phenomenon in which thoughts, emotions, and behavior contribute significantly to pain perception and pain outcomes. Although it is beyond the scope of this review to discuss all the possible contributing and potentially ameliorating factors and their measurement, a comprehensive assessment of pain for interdisciplinary treatment could also include an assessment of underlying pain mechanisms, the perceived meaning of the pain, the level of pain acceptance, pain coping strategies, pain-related behavioral avoidance and/or fear (eg, kinesiophobia), and even resilience factors, including high levels of positive affect, strong social support, internal locus of control, and a sense of purpose in life.

Questionnaires presented here include the pain severity and pain interference subscales from the Brief Pain Inventory (BPI), the Defense and Veterans Pain Rating Scale (DVPRS), the Michigan Body Map (MBM), the painDETECT questionnaire (PD-Q), the Patient-Reported Outcomes Measurement Information System Pain Interference (PROMIS-PI) scales, and ambulatory assessment of pain intensity, including the use of Ecological Momentary Assessment and daily pain diaries. The description of ambulatory assessments deviates from that of the other measures, given that this methodology diverges from the standard patient-reported outcome format. This form of pain measurement, however, is becoming the gold standard and, as such, is critical for clinicians and researchers to understand. Please see Tables 1 and 2 for an overview of psychometrics and practical applications, respectively. The importance of considering other co-occurring symptoms such as sleep, mood, and fatigue will be described briefly, although their measurement will be covered in other sections of this special edition. More comprehensive measures of functional status are also described in other sections of this issue, respectively.

BRIEF PAIN INVENTORY

Description

Purpose. The BPI is used to assess pain intensity and pain interference. It was originally developed for use in cancer populations (6) but has since been validated for use in many noncancer pain populations (7,8). There is both a long and short version of this measure, with the latter being used most often in clinical trials. The short version will be reviewed herein.

Content or domains. The BPI assesses the presence of pain, pain intensity (worst, least, average, and current), pain location (body map), and the impact of pain interference on general activity, mood, walking ability, normal work, relationships with others, sleep, and life enjoyment. It also assists in documenting the types of pain medications being used and the amount of relief provided by those medications and other pain treatments.

Number of items. The BPI has a total of 15 items.

Address correspondence to Afton L. Hassett, PsyD, University of Michigan, Department of Anesthesiology, Chronic Pain and Fatigue Research Center, 24 Frank Lloyd Wright Drive, Lobby M, Ann Arbor, MI 48106. E-mail: afton@med.umich.edu.

Submitted for publication January 30, 2020; accepted in revised form April 9, 2020.
Response options/scale. The BPI uses a mixture of response sets. Item 1 asks about the presence of pain (yes/no). Item 2 is a body map and asks the respondent to shade all areas of pain and to then place an x on the area that hurts the most. Items 3 to 6 (pain intensity items: worst, least, average, and current) utilize an 11-point rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine). Item 7 is an open-ended response field for listing pain medications. Item 8 (percentage of pain relief from medications or pain treatments) uses a 0% (no relief) to 100% (complete relief) response scale. Item 9 has seven parts representing different aspects of pain interference (general activity, mood, walking ability, normal work, relationships with others, sleep, and life enjoyment). The response set for pain interference ranges between 0 (does not interfere) and 10 (completely interferes).

Recall period for items. The time frame for the BPI is typically the past week, but some versions also use the past 24 hours.

Cost to use. Licensing fees and $100 processing fees may be applied to use. Contact MD Anderson Cancer Center to inquire about fees for specific uses.

How to obtain. The BPI is copyrighted and validated intellectual property. If interested, the contact information following contact information may be used: Department of System Research, Attention: Assessment Tools, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030 (E-mail: symptomresearch@mdanderson.org).

Practical application

Method of administration. The BPI can be administered as a paper/pencil form, a computerized form, or an interview.

Scoring. Some of the items represent single-item values and do not require scoring (eg, pain relief). The pain severity score is obtained by calculating the mean of the four pain severity items. The pain interference score is obtained by calculating the mean of the seven pain interference items. The BPI is easily scored by hand.

Score interpretation. The pain severity score ranges between 0 and 10, with larger values representing greater pain severity. The pain interference score similarly has a range of 0 to 10, with larger values representing greater pain interference.

Respondent time to complete. It takes approximately 5 minutes to complete the BPI.

Administrative burden. Administrative burden is minimal unless an interview format is used. Typically, the form is simply handed to the participant to complete. Scoring involves calculating two means and can be accomplished in under 5 minutes.

Translations/adaptations. The BPI has been translated into over 50 languages. A complete listing of translations is available through the MD Anderson Cancer Center website (https://www.mdanderson.org/research/departments-labs-institutes/departments-divisions/symptom-research/symptom-assessment-tools/brief-pain-inventory.html).

Psychometric information

Floor and ceiling effects. Floor and ceiling effects are not often reported for the BPI but are assumed to be adequate. However, at least one study from the cardiac surgery literature suggested substantial floor effects both prior to and following surgery, but minimal ceiling effects were noted (9).

Reliability. Internal consistency has been reported as being 0.85 for the pain severity score and 0.88 for the pain interference score in noncancer pain populations (8). Test-retest reliability for daily administration up to 1 week ranges between 0.83 and 0.88 for pain severity and between 0.83 and 0.93 for pain interference (10).

Validity. Thirty-six studies of the BPI in both cancer and noncancer populations across multiple languages support a two-factor structure for the BPI (ie, pain severity and pain interference) (11). Construct validity has been supported for the generic use of the BPI with chronic pain in over 72 studies (7), and it has been used to assess pain in over 400 studies with a wide variety of painful conditions. For example, in patients with arthritis, the BPI pain severity score correlated \( r = 0.74 \) with the bodily pain scale of the Short Form 36 (a generic index of pain severity). Similarly, the BPI pain interference score correlated with the Chronic Pain Grade Disability Index \( r = 0.81 \) and with the Health Assessment Questionnaire Disability Index (a disease-specific measure of functional interference) \( r = -0.69 \) (7).

Responsiveness. The BPI has demonstrated responsiveness to change in both pharmacological and nonpharmacological treatments (7,8,11).

Minimally important differences. In chronic pain states a two- to three-point change or 30% improvement in pain severity is considered meaningful. In a pharmacological study of fibromyalgia, data were pooled across 12-week treatment periods from four randomized controlled trials and anchored against the patients’ Global Impressions of Improvement scale. For the BPI pain severity score, a 2.2-point change corresponded with a 34% reduction from baseline scores (12). Few studies have estimated the minimally important difference (MID) for the BPI pain interference. One study of bone metastases that did, however, suggested an effect size of 0.05 SD (13).
Generalizability. As stated, the BPI has been validated for use in multiple chronic pain conditions, both clinically and for research purposes. The constructs of pain severity and pain interference do not appear to be unique to any one form of pain, and therefore the items of this instrument appear to be relevant to chronic pain generally.

Use in clinical trials. Pain severity and pain interference as constructs are recommended as core domains of assessment for clinical trials involving pain interventions. The BPI pain severity score and the BPI pain interference score are suggested indices for capturing these domains in clinical trials (14).

Critical appraisal of overall value to the rheumatology community

Strengths. The BPI was designed to be a monitoring tool for change in pain and its impact over time. Numerous studies support its valid use in this capacity.

Caveats and cautions. The BPI is considered an industry standard for the assessment of pain and its impact. It possesses strong psychometric properties for its pain severity score and its pain interference score. Far less is known about the other features of this instrument (eg, body map, medications, and pain relief), and these other features are rarely reported.

Clinical usability. The BPI is recommended for use in clinical settings to monitor pain severity and pain interference.

Research usability. The BPI is also recommended for use in research because it is easily administered and possesses low patient burden.

DEFENSE AND VETERANS PAIN RATING SCALE

Description

Purpose. The DVPRS was developed to standardize assessment of pain across Department of Defense and Veterans Health Administration health systems (15,16). Its first iteration incorporated the Faces Rating Scale–Revised, for which the International Association for the Study of Pain holds the copyright. To avoid copyright infringement, an alternative facial expressions scale was developed for a second version of the instrument (DVPRS version 2.0).

Content or domains. The DVPRS consists of a pain intensity item and four supplemental items. The supplemental items ask about how pain is interfering with usual activity, sleep, mood, and stress during the past 24 hours.

Number of items. The DVPRS consists of five items (a pain intensity item and four supplemental items).

Response options/scales. The pain intensity item comprises an 11-point numeric rating scale (NRS) (0-10) that incorporates the following: 1) descriptions for each integer on the scale (eg, 0 = no pain, 1 = hardly notice pain, 5 = interrupts some activities, 10 = as bad as it could be/nothing else matters); 2) a traffic light coding system that groups pain intensity into mild (green: 1-4), moderate (yellow: 5-6), and severe (red: 7-10); and 3) a facial expressions scale. Four supplemental items are accompanied by an 11-point NRS in which 0 is anchored as “does not interfere” and 10 as “completely interferes.”

Recall period for items. The recall period for the pain intensity item of the DVPRS is the current time. The recall period for the pain interference items is the past 24 hours.

Cost to use. The DVPRS is free for clinicians and researchers to use with the proviso that the instrument remains unaltered.

How to obtain. The DVPRS can be downloaded from the Defense & Veterans Center for Integrative Pain Management website (https://www.dvcipm.org/clinical-resources/defense-veterans-pain-rating-scale-dvprs/).

Practical application

Method of administration. A paper-based version of the DVPRS can be completed by the patient independently. Alternatively, responses can be obtained through an interview of the patient by the clinician.

Scoring. Separate scores are recorded for pain intensity and each of the supplemental items (interference with activity, sleep, mood, and stress over the past 24 hours). Each item has a possible range of 0 to 10.

Score interpretation. Higher scores on DVPRS items indicate greater pain intensity or greater pain interference.

Respondent time to complete. The DVPRS takes approximately 3 minutes to complete (17).

Administrative burden. Given its ease of access, minimal time required for completion, and the small number of items, the DVPRS presents a low administrative burden.

Translations/adaptations. Spanish and Vietnamese versions of the scale are available (https://www.dvcipm.org/clinical-resources/defense-veterans-pain-rating-scale-dvprs/).
Psychometric information

A systematic literature search of manuscripts written in English through January 2017 restricted to adults with chronic (3 or more months) musculoskeletal pain was unable to identify studies of the reliability, validity, responsiveness to change or MID for the DVPRS (18). However, studies using the instrument, including its postdevelopment preliminary evaluation, have examined its psychometric properties in less restrictive patient cohorts.

Floor and ceiling effects. Floor and ceiling effects of the DVPRS are yet to be investigated.

Reliability. Evaluation of the preliminary version of the DVPRS (version 1.0) using data from inpatients and outpatients with predominantly chronic noncancer pain or acute postoperative pain demonstrated a high level of internal consistency reliability (Cronbach’s α = 0.90 for the five items) (16). Subsequent examination of the DVPRS version 2.0 using data from active-duty military personnel and veterans also demonstrated acceptable internal consistency reliability (Cronbach’s α = 0.87) (15). Acceptable test-retest reliability for the pain intensity item (Pearson’s r = 0.64; P < 0.001) and the supplemental items (Pearson’s r of more than 0.70 for all items; P < 0.001) has also been reported (15).

Validity. Evaluation of the construct validity of the preliminary version of the DVPRS (version 1.0) using principal component factor analysis found that one factor accounted for 72% of the variance in the measure (factor loadings for all five items of more than 0.82) (16). Subsequent examination of DPRS version 2.0 using data from active-duty military personnel and veterans supported a single-factor structure, explaining 66% of the variance in the measure (factor loadings for all five items of 0.53 or more) (15). However, in this study, a two-factor solution was supported when factor extraction was fixed, indicating the need for further evaluation and confirmatory factor analysis.

Preliminary evaluation of the content validity of the word descriptions integrated alongside the 11-point NRS demonstrated excellent agreement (intraclass correlation coefficient [ICC] = 0.94) (16).

Evidence supports the concurrent validity of the pain interference items of the DVPRS (19). The mean of the four DVPRS pain interference item scores has been shown to correlate with scores on the Pain Disability Questionnaire (PDQ) (Spearman’s ρ = 0.69; P < 0.001) and the Veterans RAND 36-item Health Survey bodily pain subscale (Spearman’s ρ = −0.65; P < 0.001), physical component subscale (Spearman’s ρ = −0.37; P < 0.001), and mental component subscale (Spearman’s ρ = −0.46; P < 0.001) (19). When examined individually, the DVPRS pain interference on activity item correlated with the PDQ functional status component (Spearman’s ρ = 0.64; P < 0.001); DVPRS pain interference on mood and stress items correlated with scores on the PDQ psychosocial status component and Beck Depression Inventory II scores; and the DVPRS pain interference on sleep item correlated with scores on the Insomnia Severity Index (Spearman’s ρ = 0.57; P < 0.001).

Responsiveness. The responsiveness to change of the DVPRS is yet to be investigated.

Minimally important differences. Minimal clinically important differences of the DVPRS items have not been empirically determined.

Generalizability. Given the context within which the DVPRS has been evaluated, generalizability is limited to active-duty military personnel and veterans.

Use in clinical trials. A search of ClinicalTrials.gov with the term “DVPRS” in January 2020 returned a list of 32 registered trials. As might be expected, the vast majority were conducted, or planned to be conducted, in military contexts or with veteran participants.

Critical appraisal of overall value to the rheumatology community

In the absence of comprehensive psychometric evaluation data specific to rheumatic and musculoskeletal disorders, the value of the DVPRS to the rheumatology community is arguably restricted to use in military contexts.

MICHIGAN BODY MAP

Description

Purpose. The MBM was developed to address the critical need for the availability of a body map that provides a quantifiable score and would be easy to use in clinical and research settings (20,21). The MBM has since been used in a wide range of studies in rheumatologic populations to assess the presence and location of chronic pain in 35 body areas (22–31).

Content or domains. The MBM consists of a graphic manikin that depicts the front and back sides of an androgynous figure. Check boxes appear over 35 areas commonly reported as being painful (eg, lower back, neck, knees, wrists, hips, and head).

Number of items. The MBM consists of one activity: indicating areas of the body affected by chronic pain.
Response options/scale. Respondents are directed as follows: “On the image below, CHECK ALL areas of your body where you have felt persistent or recurrent pain present for the last 3 months or longer (chronic pain).” Up to 35 body areas can be checked to indicate the locations of chronic pain.

Recall period for items. Respondents report persistent pain present over the last 3 months.

Cost to use. The MBM is free for both clinicians and researchers to use with the understanding that the measure remains unaltered and properly cited in publications.

How to obtain. The MBM and links to original publications and scoring syntax can be obtained at https://medicine.umich.edu/dept/pain-research/clinical-research/michigan-body-map-mbm.

Practical application

Method of administration. The MBM is a self-report measure and can be administered using either a pen and paper form or an electronic version of the MBM (eMBM) (32). The respondent is asked to check every box that indicates an area where they have experienced chronic pain.

Scoring. Although the MBM is predominantly used to indicated areas of chronic pain, a score can be derived by totaling the number of body areas impacted.

Score interpretation. In addition to providing information about the location of a patient’s chronic pain, the MBM is thought to be most useful for showing the degree to which a patient’s pain is widespread. The endorsement of numerous body areas and/or the endorsement of locations across several body zones (eg, right upper quadrant, right lower quadrant, left upper quadrant, left lower quadrant, and head) suggest the presence of a more centralized pain state (ie, fibromyalgia) (33).

Respondent time to complete. The MBM takes less than 1 minute to complete (21).

Administrative burden. There is little burden associated with this measure. It is readily available in paper and electronic forms, is easy to understand, takes only a few minutes for respondents to complete, and requires no specific training to score and interpret.

Translations/adaptations. The MBM has been translated into German, Chinese, Portuguese, and Yiddish, although none of these translations have undergone formal validation.

Psychometric information

Floor and ceiling effects. Floor and ceiling effects have yet to be investigated in the MBM or eMBM.

Reliability. In a study evaluating test-retest reliability, patients completed the MBM and then returned to the clinic for a retest 1 to 2 weeks later. The Wilcoxon signed-rank test and dependent samples t-test were used to assess the test-retest reliability of the MBM. Half of respondents had zero or one discrepant body areas between the two administrations. Percentage agreement for each body part from first administration to second ranged from 85% to 100%. The correlation between total number of body areas checked at each administration was positive and statistically significant. The time to complete the MBM was similar between the initial and follow-up administrations 1 to 2 weeks later (21).

Validity. In a study of convergent and discriminant validity, patients with pain (n = 237) completed the MBM and the following commonly used measures of pain outcomes: the BPI (pain severity and pain interference subscales), the PD-Q, the Oswestry Disability Index, the Catastrophizing Subscale from the Coping Strategies Questionnaire, and the Hospital Anxiety and Depression Scale (HADS). The correlations between the MBM and each of the pain-related constructs were positive. Correlations of this magnitude suggest that less than 17% of the variance in each of these other scales overlaps with the MBM measure. Thus, in assessing the degree to which pain is pain widespread, the MBM is assessing a somewhat unique construct that has positive associations with other metrics of pain (21).

Responsiveness. The MBM is typically used as a method of assessing pain location and is commonly used as a predictor variable when it is thought that the number of painful sites endorsed could be informative.

Minimally important differences. Not applicable.

Generalizability. The MBM has been translated into several languages and is used in a broad array of settings, including in different countries, for noninflammatory and inflammatory pain conditions, and in surgical settings. Such wide use supports the generalizability of the MBM.

Use in clinical trials. The MBM has been or is being used as an assessment measure in a number of prospective cohort studies and clinical trials for patients with both acute and chronic pain.
Critical appraisal of overall value to the rheumatology community

**Strengths.** The MBM was designed to address a need in pain location assessment—to provide a validated body map that yields a quantifiable measure of the spread of pain across the body.

**Caveats and cautions.** The MBM is still relatively new, and more validation work in diverse patient populations is needed.

**Clinical usability.** The MBM is recommended for use in clinical settings to assess and monitor the location of pain and changes in location over time.

**Research usability.** The MBM is recommended for use in research because it provides a score from 0 to 35 that can easily be used to assess whether a patient’s pain is focal or widespread. Furthermore, the MBM can also be used for the assessment of the fibromyalgia survey criteria (33,34). Of the 35 body areas denoted in the MBM, 19 correspond with those in the Widespread Pain Index, which is one of two components of the fibromyalgia survey criteria (34). This latter feature has made the body map a particularly helpful tool for the assessment of fibromyalgia-like or centralized pain in many populations (22,24–26,30,31,35,36). The presence of pain that is more widespread, as opposed to localized, has implications for treatment.

**PAINDETECT QUESTIONNAIRE**

**Description**

**Purpose.** The PD-Q was developed as a screening tool to determine the likelihood of the presence of pain of neuropathic origin (37).

**Content or domains.** The PD-Q includes three questions about pain intensity (current pain, the strongest pain during the past 4 weeks, and how strong the pain was during the past 4 weeks on average). A body manikin is used to collect information about the main area of pain. Seven items inquire about the presence and quality of neuropathic pain symptoms (eg, burning sensation or tingling/prickling sensations). One item asks about the course of pain over time, and one item asks whether pain radiates to other regions of the body.

**Number of items.** The PD-Q includes 13 items. Responses to nine of these items are summed to derive a total PD-Q score.

**Response options/scales.** The three questions about pain intensity are accompanied by 11-point NRS (0-10). Respondents are asked to mark their main area of pain on a body manikin. The items that ask about the presence and quality of neuropathic pain symptoms (eg, burning sensation) have Likert response options ranging from 0 (never) to 5 (very strongly). The item that asks about the course of pain over time has four response options, each accompanied by a representative illustration (persistent pain with slight fluctuations, persistent pain with pain attacks, pain attacks without pain between them, and pain attacks with pain between them). The item that asks whether pain radiates to other regions of the body also asks respondents to mark the direction in which the pain radiates on the body manikin.

**Recall period for items.** The recall period for the PD-Q is the current time or over the last 4 weeks (38).

**Cost to use.** The PD-Q is free for clinicians and researchers to use with the understanding that no alterations are made to the measure.

**How to obtain.** An English language version of the PD-Q can be retrieved from the original publication (37).

**Practical application**

**Method of administration.** The PD-Q can be completed by the patient independently using paper and pencil.

**Scoring.** Responses to nine of the 13 items are used to create a summary score, with a possible range of −1 to 38. Summed items include the seven items that ask about the presence and quality of neuropathic pain symptoms (possible range of 0 [never] to 5 [very strongly] for each item), responses to the item about the course of pain (0 = persistent pain with slight fluctuations, −1 = persistent pain with pain attacks, 1 = pain attacks without pain between them, and 1 = pain attacks with pain between them), and the item that asks about radiating pain (2 if yes, 0 if no).

**Score interpretation.** The sum of the nine scored items of the PD-Q are used to determine the likelihood of the presence of neuropathic pain. Scores of 12 or less indicate that a neuropathic component of pain is unlikely, scores from 13 to 18 are ambiguous, and scores of 19 or more indicate that a neuropathic component of pain is likely.

**Respondent time to complete.** The PD-Q takes approximately 5 minutes to complete (38).
Administrative burden. Given its ease of access and completion and the relatively small number of items, the PD-Q presents a low administrative burden.

Translations/adaptations. The PD-Q was originally developed in German. It has been extensively translated and cross-culturally adapted and is available in more than 23 languages (39).

Psychometric information

Floor and ceiling effects. In a study of inflammatory arthritides (rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis), no ceiling effect was observed for the PD-Q (40).

Reliability. A systematic critical appraisal of the measurement properties of the PD-Q determined that there was evidence for satisfactory internal consistency reliability, although the level of evidence was judged as being very low (41). Internal consistency reliability for chronic low back pain specifically has been estimated as Cronbach’s $\alpha = 0.76$ (42). Test-retest reliability of the English version of the PD-Q using pre- and postconsultation data indicated almost perfect agreement ($ICC = 0.91$, 95% confidence interval [CI] $0.88$-$0.94$) (39). In the same study, there was substantial agreement between pre-consultation scores and scores collected 1 week later ($ICC = 0.79$, 95% CI 0.70-$0.88$). Classification by neuropathic pain status performed similarly well when comparing pre- and postconsultation scores (weighted $\kappa = 0.77$, 95% CI 0.68-$0.86$), and when comparing preconsultation scores and scores collected 1 week later (weighted $\kappa = 0.69$, 95% CI 0.55-$0.83$) (39).

In a study of inflammatory arthritides (rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis), Rasch analysis indicated acceptable psychometric properties. Principal component analysis supported a one-item structure, test-retest reliability demonstrated strong agreement ($ICC = 0.94$, 95% CI 0.84-$0.98$), and classification consistency was strong (80%) (40). Rasch analysis has also supported the acceptability of the psychometric properties of the instrument when applied to a sample of patients with osteoarthritis (43).

Validity. A systematic critical evaluation of the measurement properties of the PD-Q determined that the instrument has satisfactory criterion validity but unsatisfactory content validity, although the level of evidence for both was very low (41).

The original German version of the PD-Q had a sensitivity of 85% and specificity of 80% in identifying neuropathic pain among adults with chronic low back pain (37). Sensitivity and specificity were less satisfactory for a sample of patients with neck/upper-limb conditions who completed an English version of the instrument (64% and 62%, respectively) (44).

Construct validity of a form of the PD-Q modified for use with people with knee osteoarthritis has been reported as satisfactory, although the evidence level was judged as low (41,45).

Responsiveness. The responsiveness to change of the PD-Q is yet to be investigated.

Minimally important differences. Not applicable.

Generalizability. The PD-Q has been translated, cross-culturally adapted, and tested in different countries and languages and for noninflammatory and inflammatory pain conditions. This breadth of research supports the generalizability of the instrument.

Use in clinical trials. The PD-Q has been or is being used as an outcome measure in clinical trials of pharmacological and nonpharmacological interventions for neuropathic pain.

Critical appraisal of overall value to the rheumatology community

The psychometric properties of the PD-Q indicate that it may be useful for detecting pain of neuropathic origin in patients with chronic low back pain, inflammatory arthritides, or osteoarthritis but less useful in patients with neck or upper-limb conditions.

PROMIS PAIN INTERFERENCE SCALES

Description

Purpose. The National Institutes of Health Common Fund initiative known as the PROMIS (46,47) developed a collection of psychometrically rigorous outcomes measures across multiple domains. One of these domains is pain interference, a construct that broadly assesses the consequences of pain on physical, mental, and social activities.

Content. The PROMIS-PI item banks assess the construct of pain interference, which is the extent to which pain impacts engagement in social, cognitive, emotional, physical, and recreational activities. It also includes elements of sleep and life enjoyment.

Number of items. The entire PROMIS-PI item bank is defined by 41 items; however, there are several short forms with strong relationships to the entire item bank that contain four, six, and eight items. The PROMIS-PI can also be assessed using computer adaptive testing (CAT).

Response options/scale. The PROMIS-PI item bank uses three different response sets. Each type of interference is evaluated on a scale of not at all, a little bit, somewhat, quite a
MEASURES FOR PAIN IN ADULTS

bit, and very much (response set A); never, rarely, sometimes, often, and always (response set B); or never, once a week or less, once every few days, once a day, and every few hours (response set C).

Recall period for items. All items use a 7-day recall.

Cost to use. The PROMIS-PI is free for individual and academic use. There can be fees associated with study-related services and administration for longitudinal uses.

How to obtain. HealthMeasures distributes many of the PROMIS measures (http://www.healthmeasures.net/index.php).

Practical application

Method of administration. Administration of short-form versions can be by paper and pencil or computer/tablet/smartphone. Administration of the PROMIS-PI CAT requires a computer/tablet/smartphone.

Scoring. PROMIS instruments use item-level calibrations. Although there are tables that can convert raw scores into standardized T scores, you must have complete data for this method to be valid (ie, no missing data). The most accurate method of scoring is to use a data collection tool that automatically calculates scores (eg, Research Electronic Data Capture autoscore) or the Health Measures scoring service (https://www.assessmentcenter.net/ac_scoringservice).

Score interpretation. Raw scores are converted to population T scores with a mean of 50 and an SD of 10. For example, a score of 60 is 1 SD greater than the population mean. Higher scores are indicative of more of the construct being measured; thus, in this example, 1 SD more pain interference than the population mean. Cut points for PROMIS-PI T scores include the following: 0 to 54 for normal, 55 to 59 for mild, 60 to 79 for moderate, and 70 to 80 or more for severe. Normal and mild pain interference accounts for approximately 80% of the general population, whereas moderate to severe pain interference accounts for the remaining 20% (48).

Respondent time to complete. It takes between 45 seconds and 1.6 minutes to complete this assessment, depending on the version being used.

Administrative burden. Administrative burden is minimal because the PROMIS-PI can be administered electronically or via paper and pencil. Scoring can be done by hand, by computer, or by a service.

Translations/adaptations. The PROMIS-PI has been translated into many different languages. A complete list is available on the HealthMeasures website (http://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis/available-translations).

Psychometric information

The PROMIS measures were developed using item response theory (IRT) methodology as opposed to classical test construction theory. An item pool for pain interference was developed to represent the construct. Different assessment forms using different combinations of items (eg, four, six, and eight or CAT) can be used to index the overall pool of items. The PROMIS-PI item bank has an overall Cronbach’s α of 0.99, is factor analytically unidimensional, can be reliably administered to reflect the construct with short forms of minimal burden (eg, four, six, and eight) or with CAT, and experiences minimal differential item functioning with varying respondent demographics (49).

Floor and ceiling effects. None. Endorsement of “no pain interference” is adequately scaled along with high ranges of pain interference without reaching scaling obstacles.

Reliability. The PROMIS-PI item bank retains highest information between a T score of 40 (ie, 1 SD below the population mean) to 80.4 (ie, 3 SDs above the population mean). The majority of the validation sample responses fell within this range, which is equivalent to reliability of 0.96 to 0.99 across this range. In the validation sample, no individual scores fell below a T score of 40, and only five individuals (ie, 1%) scored above 80. The degree of information/precision increased with greater numbers of items (ie, four, six, and eight) but all had reliability above 0.95 for scores ranging between 40 and 80 (49). In a rheumatologic sample, test-retest reliability of the CAT (ie, smallest number of items [eg, three]) was 0.88 for a 2-day interval (50).

Validity. Construct validity of the PROMIS-PI is supported by strong correlations with legacy measures of the same construct (ρ = 0.90), similar pain constructs (ρ = 0.84), and lesser associations with differing constructs such as mental health (r = 0.33), depression (r = 0.35), and anxiety (r = 0.35) (49). Similar support for convergent and divergent validity was found for rheumatic conditions (50).

Responsiveness. The PROMIS-PI showed a dose-response relationship with rheumatic disease severity, with responsiveness being identified even at the low end of symptoms and in individuals with minimal disease activity (50,51).
Minimally important differences. In a study of low back pain, the MID for PROMIS-PI was estimated to be between 3.5 and 5.5 points (52).

Use in clinical trials. Pain Interference is increasingly recognized as a core outcome in clinical trials for chronic pain (14).

Critical appraisal of overall value to the rheumatology community

Strengths. The IRT methodology used to develop and validate the PROMIS-PI makes it psychometrically superior to most legacy measures of the same construct, both in terms of precision and minimal patient burden. Legacy measures are static and often require all items to be completed to be valid even if the additional items add no new information—PROMIS measures do not share this weakness (49).

Caveats and cautions. The psychometric evaluation of an IRT-based instrument is different from one developed using classical test theory. Many potential users or funders do not understand how different versions of the same item bank using a short form or CAT can be equally reliable and valid indices of the same construct.

Clinical usability. When multiple domains of assessment are needed, the CAT version of the PROMIS item banks can be the most efficient. Domains can be compared with each other and interpreted easily because they all use the same T score metric.

Research usability. The static short forms are more commonly used in the research settings in which access to CAT scoring algorithms may be more limited.

AMBULATORY ASSESSMENT OF PAIN INTENSITY

Description

Other measures covered in this article rely on respondent’s retrospective recollection of their pain experience over a specified time frame, such as pain in the past week or month. In contrast, ambulatory assessment methods of measuring pain involve repeatedly assessing pain experiences in a person’s natural environment in real time (ie, report on current experience) or for proximal recall time frames (eg, since the last pain assessment or in the last day). Here the term “ambulatory assessment” refers to self-report methodologies otherwise commonly known as “ecological momentary assessment,” “experience sampling,” or “daily diaries.”

Purpose. Pain intensity is a highly variable symptom even over short time frames, and ambulatory assessment of pain is uniquely able to assess pain with high precision and reliability. Use of repeated ambulatory assessments of pain provides a number of significant advantages compared with one-time recall surveys. Ambulatory assessment of pain allows for the examination of the dynamics of pain fluctuations in daily life (53). Unlike pain ratings collected in the clinic or laboratory, ambulatory assessment approaches have good ecological validity because they reflect the experience of pain in a person’s natural environment (54,55). Furthermore, this approach does not rely on memory of past pain experiences and is therefore less subject to recall biases, including peak and recency effects on pain ratings (56–58).

Number of items/assessments. There is some inconsistency in terms of precisely how many ambulatory assessments are needed for a reliable assay of pain in clinical trial research (59–61), with one study finding that a single 24-hour rating of pain had high validity and reliability for detecting treatment effects (62) and others showing that a single momentary assessment is not adequately reliable as a trial outcome (61) and that a composite of at least 5 days of 24-hour pain ratings is necessary to reach adequate measurement reliability (63). However, ambulatory assessments are regarded as the most reliable means of assessing pain intensity (64), and this approach is consistent with the most recent US Food and Drug Administration (FDA) guidelines for the development of analgesic treatments, which require that clinical trial end points assess recent pain experience, with recall time frames of no longer than the past 24 hours (65).

Practical application

Although respondent burden is often a concern among those considering using ambulatory assessment of pain intensity, available data suggest that these methods are feasible for use in chronic pain populations. Although there are unusual examples of studies with data collection protocol compliance of less than 50% (66,67), average completion rates typically fall in the range of 85% to 90% (68,69), and completion rates are high even in populations in which chronic pain is secondary to a primary disabling condition (70–72). Another common concern in pain assessment is about reactivity to the ambulatory assessment methods, that is, concern that repeatedly asking for pain ratings in real-life settings will alter the respondent’s perceptions and ratings of pain. However, a set of studies in diverse populations has found no evidence for reactivity to repeated ambulatory assessment of pain (64,72–75).

Despite the benefits of ambulatory assessment of pain intensity, one major limitation is that methods are currently not standardized, and there is tremendous heterogeneity in ambulatory methods used across published studies (68). There is variability across studies in terms of the wording of the pain item stem, the response scale, the data input modality, the duration of assessment, the frequency of assessment, and the assessment schedule. There is no standard wording for pain items in
ambulatory assessments, and researchers have either replicated wording they find in published research, created a new item stem, or adapted wording from existing recall measures (72,76). In terms of response scale, prior studies have most commonly used a numerical rating scale, although visual analog scales and verbal ratings scales have also been popular (77). Of these three options, data on patient preference, ease of administration, responsiveness to change, and overall psychometric quality suggest that the NRS is the best overall for assessing pain intensity (69,78–84). The range of response scales also varies widely across studies, although the most common practice is to use a 0 to 10 NRS, which is consistent with common procedures in clinical care and with the current pain intensity outcome measurement recommendations from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (14).

Ambulatory pain data has been collected via paper logs/diaries (85–87), palttop computers (88), wearable devices (eg, watches) (70,89–91), and smartphone applications (92,93). With growing ubiquity of wearable technology and smartphones, use of these devices to collect ambulatory pain data in research has grown tremendously, particularly since 2010 (68). Although pain studies have collected data for various lengths of time, ranging from 1 day to more than 1 year, the most common data collection periods are 1 week or 2 continuous weeks of assessment (68). Similarly, frequency or intensity of data collection is also highly variable, although on average studies assess pain 5 times/day (68). There is also variability in the sampling schedule used across pain studies, although most studies use a time-based fixed or random sampling schedule (68). It is likely that some flexibility in ambulatory assessment methods is needed to address different types of research questions and to meet different clinical and study needs. However, there is a clear need for more rigorous psychometric evaluation and the development of clear standards for ambulatory assessment methods.

Critical appraisal of overall value to the rheumatology community

**Strengths.** Ambulatory assessment of pain intensity is uniquely capable of capturing the daily fluctuations in pain severity common in people with rheumatologic conditions. Because pain ratings are given in real time or require recall of proximal time frames, ambulatory assessment does not suffer from recall bias and provides an optimally reliable assay of pain when collected over a series of days. Because pain intensity is collected in the wild as respondents go about their daily lives, it is considered to have better ecological validity than pain ratings collected in the research laboratory or clinic. A repeated pain assessment with a maximum recall period of 24 hours for pain intensity is consistent with current FDA guidelines for the assessment of pain.

**Caveats and cautions.** Currently, there are no standardized ambulatory assessment methods for measuring pain intensity. There is also limited psychometric data regarding the various pain assessment methods that have been developed and employed.

**Clinical usability.** Logistic challenges to collecting data outside of the clinic are likely to be primary barriers to using ambulatory assessment of pain intensity clinically. This, combined with a lack of normative data and clinical cut points, currently limits the potential usefulness of this approach for clinical application.

**Research usability.** Ambulatory assessment of pain has been used for decades in the research realm, and its popularity has grown tremendously with advances in technology that facilitate data collection. The ubiquity of ambulatory assessment of pain in research continues to grow, as does the need for development and psychometric evaluation of measurement.

**CONCLUSIONS**

There are many useful measures for the assessment of pain in adult patients seen in rheumatologic settings. Using validated measures that help elucidate key features of the pain experienced by a patient, including pain severity/intensity, location, and quality, are important. Of particular interest and useful to measure, is the degree to which pain interferes with functioning. Described above are some of the most commonly used measures to address those domains. However, no measure is perfect, and most measures have decided strengths and weaknesses. The BPI is a psychometrically sound measure recommended for use in clinical settings to monitor pain severity and its impact on functioning. It is easy to administer and score, although there can be costs associated with its use. Some aspects of the BPI are rarely reported (eg, body map, medications, and pain relief) but could be considered clinically useful in the care of rheumatology patients. Another commonly used measure of pain intensity and interference is the DVPRS. The DVPRS was developed for, and has been used in primarily in, military and veteran populations. It was created to help track changes in pain intensity and interference and is considered particularly useful for monitoring within-patient symptom changes that commonly occur during transitions between different military health care providers. As such, the DVPRS would be most useful in military personnel with rheumatic conditions. Also, the PROMIS-Pi measure is an easy-to-use and psychometrically sound measure for the evaluation of pain interference. Although this measure does not include an assessment of pain severity like the BPI and DVPRS, it is available at no cost and can be administered using as few as four items. This measure is available in both CAT and static short forms of various lengths, all with strong data supportive of its reliability, validity, and responsiveness to change.
In addition to pain severity and interference, the location of pain is crucial to understand. The MBM consists of a manikin with 35 body areas that can be endorsed to indicate areas of pain. The MBM has been used to assess pain in many rheumatic populations, including osteoarthritis, rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia, and low back pain. The body map is available in paper or electronic forms at no cost, is easy for patients to understand, can be completed in a few minutes, and provides information about the location and spread of pain. In addition, the number of painful body areas can be summed to provide a score that can be used to help assess the degree to which pain is more centralized (fibromyalgia-like) (2,22,33). One limitation to this measure is that the MBM areas of bodily pain are finite, and thus not all possible areas of pain are options for patients to endorse.

As for assessing pain quality, the PD-Q is thought to be useful for the detection of neuropathic pain in patients with chronic low back pain, inflammatory arthritis, or osteoarthritis. Other data suggest that it is less useful for patients with neck or upper-limb conditions. Analysis of the instrument’s psychometric properties generally support its use as a brief screening tool. Moreover, it is easy for patients to complete, is straightforward to score, and has been extensively translated and cross-culturally validated.

Lastly, ambulatory assessment of pain intensity is increasingly ubiquitous in research and holds tremendous potential for clinical applications. Detecting fluctuations in pain as they occur in real time provides unprecedented opportunities for researchers and clinicians to better understand the characteristics and underlying mechanisms that influence pain; these insights are essential for developing individualized approaches to pain treatment. Coupled with this incredible potential is a current lack of scientific evidence supporting a standard approach to ambulatory assessment. Establishment of standard methods, population norms, and clinical cut points are necessary before ambulatory assessment can be truly useful in clinical practice. Still, ambulatory assessment of pain can provide useful insights and optimally reliable outcome measures in research regardless of the current psychometric unknowns.

Although pain assessment in the clinic typically focuses on pain itself (ie, intensity, location, and quality), pain perception is dependent not only upon noiception but also other mental and physical parameters. Thus, there is value in assessing symptom clusters related to pain. These symptom clusters allow clinicians to know what other factors are contributing to unwellness/disability and also can provide additional clinical targets for treatment, given that these symptoms are often correlated with both worsening and improvement in pain (94). One such symptom cluster that is gaining attention in both adult and pediatric chronic pain is remembered by the acronym “SPACE” (sleep, pain, affect, cognitive dysfunction, and energy/fatigue) (94,95). SPACE can be efficiently assessed using a combination of PROMIS short-form measures (eg, sleep-related impairment, pain intensity, anxiety and depression, cognition, and fatigue scales) or by using one of the PROMIS profiles such as the PROMIS 29+2 (96), which contains scales assessing each of the elements within SPACE.

This symptom cluster can also be assessed using a combination of legacy measures for each symptom, which have been reviewed elsewhere (94) (eg, the Pittsburg Sleep Quality Index, the MBM, the PD-Q [reviewed above], the HADS, the Multidimensional Inventory of Subjective Cognitive Impairment, and the Multidimensional Fatigue Inventory). When such comorbid symptoms are identified, addressing these, especially sleep and mood, can have an appreciable impact on pain and functioning (97,98).

Pain is complex—no single measure can adequately account for the experience and toll of living with chronic pain. The measures described here and those from past similar publications (1) can be used to form the substrate for clinical pain assessment. Yet, other symptoms that commonly co-occur with chronic pain are also critical to assess (eg, SPACE symptoms). A comprehensive understanding of an individual’s pain experience through the use of validated measures can help personalize treatment, with the goal of achieving optimum outcomes.

AUTHOR CONTRIBUTIONS

All authors drafted the article, revised it critically for important intellectual content, and approved the final version to be published.

REFERENCES

1. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP), Arthritis Care Res (Hoboken) 2011;63 Suppl 11:S240–52.
2. Clauw DJ. Fibromyalgia: a clinical review. JAMA 2014;311:1547–55.
3. Clauw DJ, Hassett AL. The role of centralised pain in osteoarthritis. Clin Exp Rheumatol 2017;35 Suppl 107:79–84.
4. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther 2011;13:211.
5. Lee YC, Bingham CO, Edwards RR, Marder W, Phillips K, Bolster MB, et al. Association between pain sensitization and disease activity in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Care Res (Hoboken) 2018;70:197–204.
6. Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197–210.
7. Keller S, Bann CM, Doddi SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004;20:309–18.
8. Tan G, Jensen MP, Thornby JI, Shantil BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004;5:133–7.
9. Gjelo KH, Stenseth R, Wahba A, Lydersen S, Klepstad P. Validation of the brief pain inventory in patients six months after cardiac surgery. J Pain Symptom Manage 2007;34:648–56.
10. Mendoza T, Mayne T, Ruble D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain 2006;10:353–61.
11. Cleeland C. The brief pain inventory: user guide. Houston (TX): MD Anderson Cancer Center; 2009.
12. Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken) 2011;63:821–6.
13. Wong K, Zeng L, Zhang L, Bedard G, Wong E, Tsao M, et al. Minimal clinically important differences in the brief pain inventory in patients with bone metastases. Support Care Cancer 2013;21:1893–9.
14. Dworink RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005;113:9–19.
15. Polomano RC, Galloway KT, Kent ML, Brandon-Edwards H, Kwon KN, Morales C, et al. Psychometric testing of the Defense and Veterans Pain Rating Scale (DVPRS): a new pain scale for military population. Pain Med 2016;17:1505–19.
16. Buckenmaier CC, Galloway KT, Polomano RC, McDuffie M, Kwon N, Galagher RM. Preliminary validation of the Defense and Veterans Pain Rating Scale (DVPRS) in a military population. Pain Med 2013;14:110–23.
17. Haun JN, Ballistria LM, Melillo C, Standifer M, Kip K, Paykel J, et al. A mobile and web-based self-directed complementary and integrative health program for veterans and their partners (Mission Reconnect): protocol for a mixed-methods randomized controlled trial. JMIR Res Protoc 2019;8:e13666.
18. VA evidence synthesis program evidence briefs. Washington (DC): Department of Veterans Affairs; 2011.
19. Nauft TH, Hull A, Hollday SB, Sullivan P, Sandbrink F. Concurrent validity of the defense and veterans pain rating scale in VA outpatients. Pain Med 2015;16:2152–61.
20. Hassett AL, Wasserman R, Goesling J, Rakovits K, Shi B, Brummett CM. Longitudinal assessment of pain outcomes in the clinical setting: development of the "APOLO" electronic data capture system. Reg Anesth Pain Med 2012;37:398–402.
21. Brummett CM, Bakshi RR, Goesling J, Leung D, Moser SE, Zolars JW, et al. Preliminary validation of the Michigan Body Map. Pain 2016;157:1205–12.
22. Brummett CM, Urquhart AG, Hassett AL, Tsdikov A, Hallstrom BR, Wood NI, et al. Characteristics of fibromyalgia independently predict poorer long-term analgesic outcomes following total knee and hip arthroplasty. Arthritis Rheumatol 2015;67:1386–94.
23. Goesling J, Brummett CM, Meraj TS, Moser SE, Hassett AL, Ditre JW. Associations between pain, current tobacco smoking, depression, and fibromyalgia status among treatment-seeking chronic pain patients. Pain Med 2015;16:1433–42.
24. Brummett CM, Janda AM, Schueller CM, Tsdikov A, Morris M, Williams DA, et al. Survey criteria for fibromyalgia independently predict increased postoperative opioid consumption after lower-extremity joint arthroplasty: a prospective, observational cohort study. Anesthesiology 2013;119:1434–43.
25. Janda AM, As-Sanie S, Rajala B, Tsdikov A, Moser SE, Clauw DJ, et al. Fibromyalgia survey criteria is associated with increased postoperative opioid consumption in women undergoing hysterectomy. Anesthesiology 2015;122:1103–11.
26. Neville SJ, Clauw AD, Moser SE, Urquhart AG, Clauw DJ, Brummett CM, et al. Association between the 2011 fibromyalgia survey criteria and multi-site pain sensitivity in knee osteoarthritis. Clin J Pain 2018;34:909–17.
27. Scott JR, Hassett AL, Schnipf AD, Brummett CM, Harris RE, Clauw DJ, et al. Moderate alcohol consumption is associated with reduced pain and fibromyalgia symptoms in chronic pain patients. Pain Med 2018;19:2515–27.
28. Hassett AL, Goesling J, Mathur SN, Moser SE, Brummett CM, Sibley KT. Affect and low back pain: more to consider than the influence of negative affect alone. Clin J Pain 2016;32:907–14.
29. Hassett AL, Hilliard PE, Goesling J, Clauw DJ, Harte SE, Brummett CM. Reports of chronic pain in childhood and adolescence among patients at a tertiary care pain clinic. J Pain 2013;14:1390–7.
30. Brummett CM, Goesling J, Tsodikov A, Meraj TS, Wasserman RA, Clauw DJ, et al. Prevalence of the fibromyalgia phenotype in spine pain patients presenting to a tertiary care pain clinic and the potential treatment implications. Arthritis Rheum 2013;65:3285–92.
31. Brummett CM, Lohse AG, Tsdikov A, Moser SE, Meraj TS, Goesling J, et al. Aberrant analgesic response to medial branch blocks in patients with characteristics of fibromyalgia [published erratum appears in Reg Anesth Pain Med 2015;40:735]. Reg Anesth Pain Med 2015;40:249–54.
32. Hassett AL, Pierce J, Goesling J, Fritsch L, Bakshi RR, Kohns DJ, et al. Initial validation of the electronic form of the Michigan Body Map. Reg Anesth Pain Med 2019. E-pub ahead of print.
33. Brummett CM, Hassett AL, Brummett KA, Clauw DJ, Williams DA. The Michigan Body Map and its use in assessing the American College of Rheumatology survey criteria for fibromyalgia [abstract]. Arthritis Rheum 2011;63 Suppl:S368.
34. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RS, et al. Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR preliminary diagnostic criteria for fibromyalgia. J Rheumatol 2011;38:1113–22.
35. Schrefl A, Moser S, Harte SE, Basu N, Kaplan C, Kolarik E, et al. Top down or bottom up? An observational investigation of improvement in fibromyalgia symptoms following hip and knee replacement. Rheumatology (Oxford) 2020;59:601–602.
36. Mortfi D, Larach DB, Moser SE, Goesling J, Hassett AL, Brummett CM. Median branch radiofrequency ablation outcomes in patients with centralized pain. Reg Anesth Pain Med 2019. E-pub ahead of print.
37. Freynhagen R, Baron R, Goekl U, Tölle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 2006;22:1911–20.
38. Carlesco LC, Hawker GA, Hochman JR, Davis AM. Assessing joint pain and function in the clinic. In: Arendt-Nielsen L, Perrot S, editors. Pain in the joints. Philadelphia: Wolters Kluwer Health; 2017, p. 93–116.
39. Tampin B, Briffa NK, Goucke R, Slater H. Identification of neuropathic pain in patients with neck/upper limb pain: application of a grading system and screening tools. Pain 2013;154:2813–22.

40. Rifbjerg-Madsen S, Wahrens EE, Danneskild-Samsoe B, Armos K. Psychometric properties of the painDETECT questionnaire in rheumatoid arthritis, psoriatic arthritis and spondyloarthritides: Rasch analysis and test-retest reliability. Health Qual Life Outcomes 2017;15:110.
41. Mathieson S, Maher CG, Terwee CB, Folly de Campos T, Lin CW. Core outcome measures for chronic pain clinical trials: protocol for a mixed-methods randomized controlled trial. JMIR Res Protoc 2019;8:e13666.
42. Cappelleri JC, Koduru V, Bienen EJ, Sadosky A. A cross-sectional section study. Arthritis Care Res (Hoboken) 2015;67:519–28.
45. Hochman JR, Gagliese L, Davis AM, Hawker GA. Neuropathic pain symptoms in a community knee OA cohort. Osteoarthritis Cartilage 2011;19:647–54.

46. Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 2010;63:1179–94.

47. Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007;45 Suppl 1:S3–11.

48. HealthMeasures. PROMIS score cut points. 2020. URL: http://www.healthmeasures.net/score-and-interpret/interpret-scores/promis/promis-score-cut-points.

49. Amtmann D, Cook KF, Jensen MP, Chen WH, Choi S, Revicki D, et al. Development of a PROMIS item bank to measure pain interference. Pain 2010;150:173–82.

50. Bartlett SJ, Orbai AM, Duncan T, DeLeon E, Ruffing V, Clegg-Smith K, et al. Reliability and validity of selected PROMIS measures in people with rheumatoid arthritis. PLoS One 2015;10:e0138543.

51. Askew RL, Cook KF, Revicki DA, Cella D, Amtmann D. Evidence from diverse clinical populations supported clinical validity of PROMIS pain interference and pain behavior. J Clin Epidemiol 2016;73:103–11.

52. Amtmann D, Kim J, Chung H, Askew RL, Park R, Cook KF. Minimally important differences for Patient Reported Outcomes Measurement Information System pain interference for individuals with back pain. J Pain Res 2016;9:251–5.

53. Schneider S, Junghaenel DU, Keefe FJ, Schwartz JE, Stone AA, Broderick JE. Individual differences in the day-to-day variability of pain, fatigue, and well-being in patients with rheumatic disease: associations with psychological variables. Pain 2012;153:819–22.

54. Stone AA, Broderick JE, Junghaenel DU, Schneider S, Schwartz JE. PROMIS fatigue, pain intensity, pain interference, pain behavior, physical function, depression, anxiety, and anger scales demonstrate ecological validity. J Clin Epidemiol 2016;74:194–206.

55. Stone AA, Shiffman SS. Ecological validity for patient reported outcomes. In: Steptoe A, editor. Handbook of behavioral medicine: methods and applications. New York: Springer Science+Business Media; 2010. p. 99–112.

56. Schneider S, Stone AA, Schwartz JE, Broderick JE. Peak and end effects in patients’ daily recall of pain and fatigue: a within-subjects analysis. J Pain 2011;12:228–35.

57. Stone AA, Schwartz JE, Broderick JE, Shiffman SS. Variability of momentary pain predicts recall of weekly pain: a consequence of the peak (or salience) memory heuristic. Pers Soc Psychol Bull 2005;31:1340–6.

58. Stone AA, Broderick JE, Kaell AT, DelesPau PA, Porter LE. Does the peak-end phenomenon observed in laboratory pain studies apply to real-world pain in rheumatoid arthritis? [original report]. J Pain 2000;1:212–7.

59. Jensen MP, Hu X, Potts SL, Gould EM. Measuring outcomes in pain clinical trials: the importance of empirical support for measure selection. Clin J Pain 2014;30:744–8.

60. Stone AA, Schneider S, Broderick JE, Schwartz JE. Single-day pain assessments as clinical outcomes: not so fast. Clin J Pain 2014;30:739–43.

61. Stone AA, Broderick JE, Kaell AT. Single momentary assessments are not reliable outcomes for clinical trials. Contemp Clin Trials 2010;31:466–72.

62. Jensen MP, Hu X, Potts SL, Gould EM. Single vs composite measures of pain intensity: relative sensitivity for detecting treatment effects. Pain 2013;154:534–8.

63. Heapy A, Dziura J, Buta E, Goulet J, Kulas JF, Kerns RD. Using multiple daily pain ratings to improve reliability and assay sensitivity: how many is enough? [original report]. J Pain 2014;15:1360–5.

64. Sniffen S, Stone AA, Hufford MR. Ecological momentary assessment. Annu Rev Clin Psychol 2008;4:1–32.

65. US Food and Drug Administration. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. URL: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims.

66. Broderick JE, Schwartz JE, Shiffman S, Hufford MR, Stone AA. Signaling does not adequately improve diary compliance. Ann Behav Med 2003;26:139–48.

67. Robinson K, Kennedy N, Harmon D. The flow experiences of people with chronic pain. OTJR (Thorofare N J) 2012;32:104–12.

68. May M, Junghaenel DU, Ono M, Stone AA, Schneider S. Ecological momentary assessment methodology in chronic pain research: a systematic review. J Pain 2018;19:699–716.

69. Ono M, Schneider S, Junghaenel DU, Stone AA. What affects the completion of ecological momentary assessments in chronic pain research? An individual patient data meta-analysis. J Med Internet Res 2019;21:e11398.

70. Krazt AL, Kalpakjian CZ, Hanks RA. Are intensive data collection methods in pain research feasible in those with physical disability? A study in persons with chronic pain and spinal cord injury. Qual Life Res 2017;26:587–600.

71. Carlozzi NE, Schilling S, Freedman J, Kalpakjian CZ, Krazt AL. The reliability of end of day and ecological momentary assessments of pain and pain interference in individuals with spinal cord injury. Qual Life Res 2018;27:3003–12.

72. Krazt AL, Murphy SL, Braley TJ. Ecological momentary assessment of pain, fatigue, depressive, and cognitive symptoms reveals significant daily variability in multiple sclerosis. Arch Phys Med Rehabil 2017;98:2142–50.

73. Stone AA, Broderick JE, Schwartz JE, Shiffman S, Litcher-Kelly L, Calvanese P. Intensive momentary reporting of pain with an electronic diary: reactivity, compliance, and patient satisfaction. Pain 2003;104:343–51.

74. Cruise CE, Broderick J, Porter L, Kaell A, Stone AA. Reactive effects of diary self-assessment in chronic pain patients. Pain 1996;67:253–8.

75. Von Baeyer CL. Reactive effects of measurement of pain. Clin J Pain 1994;10:18–21.

76. Schneider S, Choi SW, Junghaenel DU, Schwartz JE, Stone AA. Psychometric characteristics of daily diaries for the Patient-Reported Outcomes Measurement Information System (PROMIS®): a preliminary investigation. Qual Life Res 2013;22:1859–69.

77. Safikhani S, Gries KS, Trudeau JJ, Reasner D, Rüdell K, Coons SJ, et al. Response scale selection in adult pain measures: results from a literature review. J Patient Rep Outcomes 2017;2:40.

78. Ritter PL, Gonzalez VM, Laurent DD, Lorig KR. Measurement of pain using the visual numeric scale. J Rheumatol 2006;33:574–80.

79. Jackson D, Horn S, Kersten P, Turner-Stokes L. Development of a pictorial scale of pain intensity for patients with communication impairments: initial validation in a general population. Clin Med (Lond) 2006;6:580–5.

80. Gonzalez-Fernandez M, Ghosh N, Ellison T, McLeod JC, Pelle-tier CA, Williams K. Moving beyond the limitations of the visual analog scale for measuring pain: novel use of the general labeled magnitude scale in a clinical setting. Am J Phys Med Rehabil 2014;93:75–81.

81. Gagliese L, Weizblit N, Ellis W, Chan VW. The measurement of post-operative pain: a comparison of intensity scales in younger and older surgical patients. Pain 2005;117:412–20.
82. Chien CW, Bagraith KS, Khan A, Deen M, Strong J. Comparative responsiveness of verbal and numerical rating scales to measure pain intensity in patients with chronic pain. J Pain 2013;14:1653–62.

83. Chanques G, Viel E, Constantin JM, Jung B, de Lattre S, Carr J, et al. The measurement of pain in intensive care unit: comparison of 5 self-report intensity scales. Pain 2010;151:711–21.

84. Rothaug J, Weiss T, Meissner W. How simple can it get? Measuring pain with NRS items or binary items. Clin J Pain 2013;29:224–32.

85. Zautra AJ, Davis MC, Reich JW, Nicassario P, Tennen H, Finan P, et al. Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. J Consult Clin Psychol 2008;76:408–21.

86. Glaros AG, Hanson AH, Ryen CC. Headache and oral parafunctional behaviors. Appl Psychophysiol Biofeedback 2014;39:59–66.

87. Glaros AG, Marszalek JM, Williams KB. Longitudinal multilevel modeling of facial pain, muscle tension, and stress. J Dent Res 2016;95:416–22.

88. Cauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial [published errata appear in Clin Ther 2009;31:446 and Clin Ther 2009;31:1617]. Clin Ther 2008;30:1988–2004.

89. Alschuler KN, Hoodin F, Murphy SL, Rice J, Geisser ME. Factors contributing to physical activity in a chronic low back pain clinical sample: a comprehensive analysis using continuous ambulatory monitoring. Pain 2011;152:2521–7.

90. Murphy SL, Strasburg DM, Lyden AK, Smith DM, Koliba JF, Dadabhoy DP, et al. Effects of activity strategy training on pain and physical activity in older adults with knee or hip osteoarthritis: a pilot study. Arthritis Rheum 2008;59:1480–7.

91. Whibley D, Braley TJ, Kratz AL, Murphy SL. Transient effects of sleep on next-day pain and fatigue in older adults with symptomatic osteoarthritis. J Pain 2019;20:1373–82.

92. Wolf LD, Davis MC, Yeung EW, Tennen HA. The within-day relation between lonely episodes and subsequent clinical pain in individuals with fibromyalgia: mediating role of pain cognitions. J Psychosom Res 2015;79:202–6.

93. Garcia-Palacios A, Herrero R, Belomonte MA, Castilla D, Guixeres J, Molinari G, et al. Ecological momentary assessment for chronic pain in fibromyalgia using a smartphone: a randomized crossover study. Eur J Pain 2014;18:862–72.

94. Williams DA. Phenotypic features of central sensitization. J Appl Biobehav Res 2018;23:e12135.

95. Schrepf A, Williams DA, Gallop R, Naliboff BD, Basu N, Kaplan C, et al. Sensory sensitivity and symptom severity represent unique dimensions of chronic pain: a MAPP Research Network study. Pain 2018;159:2002–11.

96. Hanmer J, Devitt B, Yu L, Tsevat J, Roberts M, Revicki D, et al. Cross-sectional validation of the PROMIS-Preference scoring system. Plos One 2018;13:e0201093.

97. McCrae CS, Williams J, Roditi D, Anderson R, Mundt JM, Miller MB, et al. Cognitive behavioral treatments for insomnia and pain in adults with comorbid chronic insomnia and fibromyalgia: clinical outcomes from the SPIN randomized controlled trial. Sleep 2019;42:zsy234.

98. Olason M, Andrasen RH, Jonsdottir IH, Kristbergsdottir H, Jansen MP. Cognitive behavioral therapy for depression and anxiety in an interdisciplinary rehabilitation program for chronic pain: a randomized controlled trial with a 3-year follow-up. Int J Behav Med 2018;25:55–66.
| Measure | Number of Items | Content/Domains | Method of Administration | Recall Period | Response Format | Range of Scores | Score Interpretation | Availability of Normative Data | Cross-cultural Validation |
|---------|----------------|-----------------|--------------------------|---------------|----------------|-----------------|----------------------|----------------------------|--------------------------|
| **BPI** | 15             | Pain severity and pain interference | Paper/pencil, computer, or CAT | 24-hr and 7 days | 11-point Likert scale with verbal anchors | Pain severity and pain interference: 0-10 | Higher scores are indicative of greater pain severity or interference. | Has been used in over 400 pain studies | Validation studies in 24 languages |
| **DVPRS** | 5              | Pain intensity and pain interference (usual activity, sleep, mood, and stress) | Paper/pencil | Pain intensity: current; pain interference: past 24 hours | 11-point numeric rating scale | Pain intensity and pain interference items: 0-10 | Higher scores are indicative of greater pain intensity or interference. | Not available | Spanish and Vietnamese versions are available† |
| **MBM** | 1 (up to 35 areas of pain can be indicated) | Pain location | Paper/pencil or computer | Pain that has persisted for more than 3 months | 35 check boxes | Number of painful body areas (0-35) | Higher scores are indicative of more areas of the body with chronic pain. | Not available | Chinese, German, Portuguese, and Yiddish versions are available. |
| **painDETECT questionnaire** | 13 (responses to 9 items are used to derive summary score) | Pain intensity, pain location and whether pain radiates, pain course, and pain quality | Paper/pencil | Currently and over the past 4 weeks | Three 11-point numeric rating scales; one illustrated question with best choice option for course of pain; one body map with accompanying question about whether pain radiates; seven six-point Likert scales for pain quality | −1 to 38 (0-38 displayed on screening scale included in instrument) | Score <12: neuropathic pain component unlikely; score ≥13-18: ambiguous (neuropathic pain component cannot be ruled out); score >19: neuropathic pain component likely | Not available | Extensively cross-culturally adapted and available in more than 23 languages |
| **PROMIS-PI** | 41, 6, or 8 | Pain Interference | Paper/pencil or computer | 7 days | Five-point numeric rating scale with verbal anchors | T scores: 0-100 | Higher scores are indicative of greater pain interference. | T score tied to population mean; 1 SD is 10 points. | Has been translated and has validation studies in numerous languages |
| **Ambulatory assessment (eg, EMA or daily diary)** | 1 | Pain intensity | Paper/pencil, computer, tablet, smartphone, wearables, short message service (text), or interactive voice response | Current, since last assessment (variable but <24 hours), or past day/24 hours | Numeric rating scale, visual analog scale, or verbal response scale | Most common: 0-10 or 0-100 | Higher scores indicate more intense pain. | Not available | Not available |

* BPI = Brief Pain Inventory; CAT = computer adaptive testing; DVPRS = Defense and Veterans Pain Rating Scale; EMA = Ecological Momentary Assessment; MBM = Michigan Body Map; PROMIS-PI = Patient-Reported Outcomes Measurement Information System Pain Interference.
† Available at [https://www.dvcipm.org/clinical-resources/defense-veterans-pain-rating-scale-dvprs/](https://www.dvcipm.org/clinical-resources/defense-veterans-pain-rating-scale-dvprs/).
| Measure               | Floor/Ceiling Effects | Reliability | Validity                  | Responsiveness | MIDs | Generalizability | Used in RCTs                                                                 |
|----------------------|-----------------------|-------------|---------------------------|----------------|------|------------------|-----------------------------------------------------------------------------|
| BPI                  | Floor: some; ceiling: minimal | Good IC; severity: 0.85; interference: 0.88. Test-retest: 0.83-0.88; interference: 0.83-0.93. | Good; scores highly correlate with other measures of severity and interference/disability (0.69-0.81). | Excellent; sensitive to treatment changes | MID of 2.2 points in severity and 0.50 SD in interference is considered meaningful | Considered a generic assessment of pain severity and interference | Used in many RCTs of varying pain conditions; recommended measure for core minimum data sets of clinical trials |
| DVPRS                | No data available     | Good IC: 0.87. Acceptable test-retest intensity: Pearson's $r = 0.64$; interference items: Pearson's $r$ all $>0.7$. | Good construct and content validity; excellent agreement between 11-point pain numeric rating scale and word descriptions (ICC 0.94). Concurrent validity of pain interference items demonstrated against established instruments | No data available | No data available | Developed and predominantly tested in military/veteran contexts | Used in RCTs with military and veteran populations |
| MBM                  | No data available     | Test-retest reliability: 0.84. | Good convergent and discriminant validity. | No data available | No data available | Used in a broad array of settings, including in different countries, for noninflammatory and inflammatory pain conditions, and in surgical settings | Used in prospective cohort studies and clinical trials for patients with acute and chronic pain |
| painDETECT           | No ceiling effects observed when tested with people with inflammatory arthritides | Low back pain IC: 0.76. Test-retest reliability: almost perfect agreement (ICC: 0.91). | Validity of English version yet to be formally investigated | No data available | No data available | Can be used to detect neuropathic components of pain in inflammatory and noninflammatory conditions | Used in RCTs of pharmacological and nonpharmacological interventions for neuropathic pain |
| PROMIS-PI            | None                  | Excellent IC: 0.96-.99. Test-retest reliability: 0.88. | Excellent; PROMIS-PI scores correlate with other measures of interference (range 0.84-0.90). | Good; sensitive to treatment changes | MID = 3.5-5.5 points considered meaningful. | Developed specifically to be a generic measure of pain interference | Recommended measure for core minimum datasets of pain studies including clinical trials |
| Ambulatory assessment (eg, EMA or daily diary) | No data available | Reliability = 0.90 with 5 days of daily ratings (1) | Excellent ecological validity (2); excellent correlation between end-of-day reports and momentary ratings of pain intensity ($rs = 0.85-0.90$) (3) | No data available | No data available | No data available | Used in many RCTs to produce an optimally reliable composite pain intensity assay and/or to examine dynamic interactions between fluctuations in pain and other biopsychosocial factors |

* BPI = Brief Pain Inventory; DVPRS = Defense and Veterans Pain Rating Scale; EMA = Ecological Momentary Assessment; IC = internal consistency; ICC = intraclass correlation coefficient; MBM = Michigan Body Map; MID = minimally important difference; PROMIS-PI = Patient-Reported Outcomes Measurement Information System Pain Interference; RCT = randomized controlled trial.